Comparative Pharmacology
Head-to-head clinical analysis: DANAZOL versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANAZOL versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
DANAZOL vs TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
300-600 mg orally twice daily; maximum 800 mg/day
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Category C
Category D/X
Androgen/Antigonadotropin
Androgen
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."